<div id="readability-page-1"><ul><li>Top 3 S&amp;P 500 Winners in a Losing Market</li></ul><p>Cencora, Inc. (NYSE:COR - Free Report) -  Leerink Partnrs lifted their FY2025 EPS estimates for shares of Cencora  in a report released on  Wednesday, August 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $15.97 per share for the year, up from their previous forecast of $15.90. The consensus estimate for Cencora's current full-year earnings is $15.37 per share. Leerink Partnrs also issued estimates for Cencora's FY2026 earnings at $17.59 EPS, FY2027 earnings at $19.32 EPS and FY2028 earnings at $21.23 EPS.</p><p>Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to analysts' expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.34 EPS. </p><ul><li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li></ul><p>A number of other research analysts also recently commented on COR. UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, April 29th. Jefferies Financial Group boosted their target price on Cencora from $275.00 to $300.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, June 30th. Wells Fargo &amp; Company upgraded Cencora from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their target price for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Morgan Stanley  set a $330.00 price target on shares of Cencora and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, July 16th. Finally, Citigroup upped their target price on shares of Cencora from $330.00 to $355.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and ten have issued  a buy rating to the stock. Based on data from MarketBeat.com, Cencora currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $309.83.</p><p><b>View Our Latest Analysis on COR</b></p><h2>Cencora Trading Up 0.6%</h2><ul><li>Teva Pharma is the way to play the re-rise of generic drugs </li></ul><p>Shares of COR opened at $280.01 on Friday. Cencora has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.52 and a current ratio of 0.90. The company's fifty day moving average is $292.63 and its 200 day moving average is $277.30. The stock has a market capitalization of $54.27 billion, a PE ratio of 29.00, a P/E/G ratio of 1.40 and a beta of 0.58. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently added to or reduced their stakes in the business. Tobam increased its stake in  Cencora by 8.9% during the 2nd quarter. Tobam now owns 10,658 shares of the company's stock worth $3,196,000 after buying an additional 875 shares during the period.  Forsta AP Fonden raised its position in  Cencora by 31.6% in the 2nd quarter. Forsta AP Fonden now owns 83,370 shares of the company's stock valued at $24,998,000 after purchasing an additional 20,000 shares in the last quarter.  Ironwood Investment Counsel LLC purchased a new position in shares of  Cencora in the 2nd quarter valued at about $203,000.  National Pension Service grew its position in shares of  Cencora by 119.3% during the second quarter. National Pension Service now owns 662,374 shares of the company's stock worth $198,613,000 after buying an additional 360,392 shares in the last quarter.  Finally, Advyzon Investment Management LLC purchased a new stake in shares of  Cencora during the second quarter worth approximately $256,000. 97.52% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Insider Activity at Cencora</h2><p>In related news, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the sale, the chief executive officer owned 42,351 shares of the company's stock, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares of the company's stock, valued at $91,271,982.06. This represents a 4.47% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is owned by corporate insiders. </p><h2>Cencora Dividend Announcement</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, August 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Cencora's dividend payout ratio  is 22.63%. </p><h2>About Cencora</h2> (Get Free Report)<p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cencora</li><li>Canadian Penny Stocks: Can They Make You Rich? </li><li>DraftKings Posts Record Quarter, Eyes Profitability</li><li>How to Invest in Biotech Stocks</li><li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li><li>How to Calculate Options Profits</li><li>Wall Street Has Left Intel for Dead—Here's Why You Shouldn’t</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cencora Right Now?</h2><p>Before you consider Cencora, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Cencora, Inc. (NYSE:COR) has seen its FY2025 EPS estimates raised by Leerink Partners to $15.97, up from $15.90. The company reported $4.00 EPS for the latest quarter, exceeding expectations. Analysts have also projected future earnings of $17.59 for FY2026, $19.32 for FY2027, and $21.23 for FY2028. Cencora's stock has a market cap of $54.27 billion, with a current price of $280.01. Institutional investors hold 97.52% of the stock, and CEO Robert P. Mauch recently sold shares valued at approximately $1.46 million.</p>

FY2025 EPS Estimates for Cencora Boosted by Leerink Partnrs